>>If I understand TrpRS therapy correctly, they will want to increase levels of the protein in the back of the eye. This cannot be accomplished with RNA-interfereing morpholinos or any other known oligo nucleic acid-based (or their derivatives) treatment --current RNAi treatments that I am aware of only decrease expression of the target gene product.<<
I brought up the RNAi companies as an attempt to refute your assertion that drugs with intracellular targets will have difficulty treating AMD. Clearly, RNAi-based therapies must enter the target cells to have any effect.
I guess I’m confused about your point. It seems to me that the dosing issue (slow-release device vs periodic direct injection) is separate from the matter of whether a drug’s target is intracellular or extracellular. Am I missing something?
Market Data 
Markets 
AI
